English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Recent reports have shown that nifedipine, a calcium channel blocker, increasesperoxisome proliferator-activated receptor-γ (PPARγ) activity. Since PPARγ agonists,such as pioglitazone and rosiglitazone, are effective in reducing non-alcoholicsteatohepatitis (NASH) and cirrhosis in animal models, we examined the protectiveeffects of nifedipine, as compared with bezafibrate, a PPARα agonist, in a NASHmodel induced by an L-methionine- and choline-deficient (MCD) diet. An MCD dietfor 20 weeks changed the color of the rat liver to yellow with an irregular surface,whereas the color of the liver in both the bezafibrate and nifedipine treatmentgroups was markedly changed to yellow-brown with a smooth surface. Furthermore,nifedipine, as well as bezafibrate, significantly prevented liver fibrosis inducedby an MCD diet, as assessed by Masson's trichrome staining, accompanied by a significantdecrease in serum AST. Overall, nifedipine treatment resulted in an improvementin NASH, similar to bezafibrate, in a rat model. In hypertensive patients withmetabolic syndrome, nifedipine may provide additional benefits, beyond its bloodpressure-lowering effects, to prevent NASH and fatty liver disease.

Nifedipine prevents hepatic fibrosis in a non-alcoholic steatohepatitis model induced by an L-methionine-and choline-deficient diet